Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Colorectal, Bladder Cancer Therapies Are Top Prospects For April US FDA Approvals

Apr 03 2020

• By Bridget Silverman

Related Content

J.P. Morgan Notebook Day 1: No Big Deals, But Plenty Of Pipeline, Commercial Highlights

Jan 14 2020

Keeping Track: Poteligeo, Onpattro, Galafold And Annovera Approved; Selinexor Submitted

Aug 13 2018

US FDA Not Changing Assessment Goals Because of Coronavirus-Mandated Telework

Mar 29 2020

Keeping Track: US FDA Refuses To File Acorda, SteadyMed NDAs

Sep 04 2017

Sanofi Pasteur Head Loew On The Vaccine Unit's Future Growth Drivers

Nov 14 2019

Urogen's Novel Formula For Urothelial Cancer Presents Unique Commercial Challenges

Sep 25 2019

Podcast: CDER’s Woodcock On COVID-19 – Missed User Fees Unlikely, But Some Work Will Be ‘Set Aside’

Apr 01 2020

Related Companies

UroGen Pharma, Ltd.

Novartis AG

Pfizer Inc.

Array BioPharma, Inc.

Eli Lilly and Company

Bristol Myers Squibb Company

Bristol Myers Squibb Company

Sanofi

Neurocrine Biosciences, Inc.

Orion

United Therapeutics Corporation

SteadyMed Ltd.

Additional Topics

United States Drug Approval Standards Drug Review Vaccines US FDA Performance Tracker Cancer BioPharmaceutical Infectious Diseases

More from US FDA Performance Tracker

More from Regulatory Trackers

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window